98%
921
2 minutes
20
Purpose: Metabolic risk factors (MetF) have emerged as the leading drivers of ischemic cardiomyopathy (ICM) worldwide. However, in patients who have already experienced myocardial ischemia/infarction, whether and in what pattern the MetF act on the heart needs to be further elucidated. This study aims to determine the adverse effects of MetF on left ventricular (LV) indexed myocardial mechano-energetic efficiency (MEEi) and dysfunction in patients with ICM, and further clarify which MetF classification is more clinically significant.
Materials And Methods: This study retrospectively included 201 patients with ICM who underwent cardiac magnetic resonance imaging (MRI) examinations, and further divided them into the following three groups according to the number of coexisting MetF: The groups with no MetF (MetF-0 group, n = 32), with 1-2 MetF (MetF-1, n = 92) and with 3-5 MetF (MetF-2, n = 77). The clinical variables and MRI-derived parameters were measured and compared among the three groups. Multivariate linear regression analysis was performed to determine independent correlation of MetF on LV MEEi and strain in ICM patients.
Results: LV global circumferential peak strain (PS) gradually decreased from MetF-0 group, through MetF-1 group, to MetF-2 group (- 9.52 ± 2.70% vs. - 7.62 ± 2.73% vs. - 6.50 ± 2.70%, P < 0.001). MetF-1 and MetF-2 groups both showed lower MEEi, lower LV global radial and longitudinal PS than MetF-0 group (Both P < 0.001), while there was no statistically significant difference between MetF-1 and MetF-2 groups (P > 0.05). Multivariate analyses indicated that the coexisting any MetF was independently associated with decreased LV MEEi (β = - 0.093, P = 0.018) and PS (Radial, β = - 0.232, P < 0.001; Circumferential, β = 0.156, P = 0.002; Longitudinal, β = 0.192, P = 0.008), and the increase in the number of coexisting MetF was only related to the reduction of circumferential PS (β = 0.238, P = 0.006).
Conclusions: Our results revealed whether coexisting any MetF, rather than coexisting a greater number of MetF, is associated with the reduction of LV myocardial mechano-energetic efficiency and dysfunction in patients with ICM, suggesting that clinicians should promptly identify and treat any coexisting MetF in the management of ICM patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224664 | PMC |
http://dx.doi.org/10.1186/s12933-025-02817-2 | DOI Listing |
Cardiovasc Diabetol
July 2025
Department of Radiology, West China Hospital, Sichuan University, 37# Guo Xue Xiang, Chengdu, 610041, Sichuan, China.
Purpose: Metabolic risk factors (MetF) have emerged as the leading drivers of ischemic cardiomyopathy (ICM) worldwide. However, in patients who have already experienced myocardial ischemia/infarction, whether and in what pattern the MetF act on the heart needs to be further elucidated. This study aims to determine the adverse effects of MetF on left ventricular (LV) indexed myocardial mechano-energetic efficiency (MEEi) and dysfunction in patients with ICM, and further clarify which MetF classification is more clinically significant.
View Article and Find Full Text PDFMalar J
May 2025
Shoklo Malaria Research Unit (SMRU), Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.
Background: Targeted interventions are often needed to accelerate malaria elimination efforts. Mass screening and treatment (MSAT) involves testing all eligible and consenting individuals in an area for malaria and treating all positive individuals simultaneously. However, there are concerns regarding the impact of MSAT.
View Article and Find Full Text PDFJ Int Soc Sports Nutr
December 2025
University of Gothenburg, Department of Food and Nutrition, and Sport Science, Centre for Health and Performance, Gothenburg, Sweden.
Objective: The study aimed to investigate the impact of nutrient timing in relation to evening exercise. Specifically, it examined the effects of pre- or post-exercise carbohydrate (CHO) ingestion on glucose metabolism, glucose regulation, and overall substrate oxidation in well-trained athletes during and after physical exercise (PE), spanning the nocturnal period and the subsequent morning.
Methods: Ten male endurance cyclists participated in the study.
Cell Mol Biol (Noisy-le-grand)
April 2025
Laboratorio de Investigación en Epidemiología Clínica y Molecular, Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Guerrero, 39089 Chilpancingo, GRO, México.
Insulin resistance (IR) is a key contributor to the development of metabolic diseases, and metformin has been shown to help mitigate IR. Long non-coding RNAs (lncRNAs) are emerging as important regulators in metabolic disorders. This study aimed to investigate the differential expression of lncRNAs in IR and assess the impact of metformin on these lncRNAs.
View Article and Find Full Text PDFFront Pharmacol
March 2025
Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.
Background: Osteoarthritis (OA) and impaired glucose tolerance (IGT) frequently coexist, leading to compounded clinical and metabolic challenges. This study investigates the effects of metformin in improving both clinical outcomes (pain, stiffness, physical function) and metabolic parameters (inflammatory markers, lipid profile, BMI) in patients with knee OA and IGT.
Methods: The study included 60 patients diagnosed with knee OA and IGT.